patients with rheumatoid arthritis, and has been documented in T-cell
LGL leukaemia with higher frequency than in the normal population. This suggests a similar immunogenetic basis for these two conditions. 13 Similarly, CLD of NK cells may be associated with autoimmune diseases.
A genetic susceptibility to develop CLD of NK cells has been suggested to be related to a distinct killer immunoglobulin receptor (KIR) repertoire that contains a high number of activating KIRs. 14, 15 In contrast to aggressive NK-cell neoplasms, EBV is exceedingly rare.
Clinical Features
T-cell LGL leukaemia preferentially affects adult patients and is infrequent in childhood. It is more common in eastern than in western countries. One-third of patients are asymptomatic and the diagnosis comprises a routine blood count that shows lymphocytosis, mild neutropenia or both. 1, 16 Asymptomatic patients may have other concomitant conditions such as myelofibrosis, eosinophilia of uncertain origin, monoclonal gammopathy, etc. The term T-cell clonopathy of unknown significance (TLUS) has been coined to designate those asymptomatic patients who represent the benign end of the clonal T-cell LGL proliferations, 17 a scenario similar to Haematological Malignancies Lymphoproliferative Disorders preservation or a reactive white pulp with mantle zone expansion (see Figure 2 ). The neoplastic LGL have a phenotype of a cytotoxic or NK cell and, unlike the normal splenic red-pulp cells, which are CD5 + CD45RO + , are negative with CD5 and CD45RO. 21 Flow cytometry shows in most T-cell LGL leukaemia cases a CD2, CD3, CD8, CD16, CD57 positive phenotype (see Figure 3) with a negative or weak CD5 and CD7 expression; CD56 is rarely positive and it has been suggested that expression of this marker is associated with a more aggressive course. 22 The diagnosis of T-cell LGL leukaemia should be confirmed by documenting clonal rearrangement of the TCR β and/or γ chain genes by Southern blot or PCR. These techniques should be performed in all suspected cases, particularly in those with a normal absolute LGL count. 16 
Pathogenesis and Molecular Features
Cytogenetic studies in T-cell LGL leukaemia and CLD of NK cells are rare; clonal abnormalities are infrequently detected, and no recurrent genetic 'marker' has been identified. 5, 28 It is now becoming evident that T-cell LGL leukaemia with a CD8 + CD4 -phenotype results from an expansion of a CD8 + terminal effector memory cytotoxic cell due to a persistent stimulation by an auto or The Spectrum of T-cell and Natural Killer-Large Granular Lymphocytic Proliferations LGLs preventing DISC formation and Fas mediated apoptosis. 
Prognosis and Survival
T-cell LGL leukaemia usually runs a chronic course in most patients with mortalities of 10-28% at four years and a median survival of >10
years. 1, 34 Most deaths are due to sepsis and rarely occur due to disease progression; transformation to large-cell lymphoma is exceedingly rare. 35 CLD of NK cells usually pursue an indolent course and a spontaneous remission has been documented in some patients. Rarely they transform in to a more aggressive disease.
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Therapy
Up to one-third of patients may never require treatment as they are asymptomatic and cytopenias are mild; a watch and wait strategy is appropriate. 1 Indications for treatment include severe neutropenia, symptomatic anaemia or thrombocytopenia and progressive disease, (i.e. organomegaly and/or rapidly raising counts). 
